Bloomberg's Mike McGlone reports why he is 'scared' over the price of gold. Spot gold smashed through $4,000 an ounce for the first time, as concerns over the US economy and a government shutdown added fresh momentum to a scorching rally.

Gold has been having a very good year.

PHILADELPHIA , Oct. 8, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against C3.ai, Inc. (NYSE: AI) ("C3.ai" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 26, 2025 through August 8, 2025 (the "Class Period"), Investor Deadline: Investors who purchased or acquired C3.ai securities during the Class Period may, no later than October 21, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

ADM accelerates growth with nutrition gains, portfolio simplification and $500-$750M in targeted cost savings.

AEO advances its digital expansion and Aerie brand momentum while optimizing stores and supply chain to fuel long-term growth.

People don't like to throw money into a sinking ship , and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do in the coming quarters.

Astera Labs ramps its PCIe 6 portfolio to power AI platforms, but Amphenol's diversified strength makes it the more compelling connectivity pick.

PYPL's new Ads Manager platform and other strategic initiatives aim to boost its business growth and global commerce expansion.

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p

Joby Aviations (JOBY) shares has jumped nearly 200% over the last year but saw a strong sell-off today after the company announced a new share offering. As George Tsilis points out, speculation surrounding Tesla's (TSLA) latest EV announcement didn't help Joby, either.

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fly-E Group, Inc. (NASDAQ: FLYE) between July 15, 2025 and August 14, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline.

PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems Ltd. (NYSE: AXTA), a leading global coatings company, will release its third quarter 2025 financial results at 6 a.m. ET on Tuesday, October 28. The release and supporting materials will be posted to Axalta's Investor Relations site .

Coinbase stock is building a cup base with a 444.65 buy point.

UBS plans a $1B loan risk transfer to free up capital as tougher Swiss rules loom following the Credit Suisse collapse.

Nextracker allegedly misled investors about the severity of project delays, backlog conversion issues, and its ability to offset these impacts on revenue.

Though Liberation Day is in the rearview mirror for the capital markets, it still continues to occupy center stage when it comes to market concerns from a forward-looking perspective.

C3.ai stock falls Tuesday, breaking a six-day winning streak. The stock is above its 50-day moving average.

HP remains a Buy, supported by solid fundamentals, robust free cash flow, and effective responses to macroeconomic challenges. HPQ's latest report showed 3% YoY revenue growth, strong cash flow, and accelerating adoption of AI PCs, now over 25% of their product mix. Anticipated rate cuts and growing AI PC demand could drive further upside, while supply chain management and tariff mitigation actions are proving effective.

Markets are good at assimilating information as it comes in, incorporating it into valuations and price action relatively quickly—but that doesn't mean they're truly efficient. By focusing on current events, markets might miss signs that point to future upside potential.

Capricor allegedly misled investors about its DMD therapy's FDA approval prospects; an FDA rejection letter citing lack of efficacy data sent shares down.